Literature DB >> 29740689

Effectiveness of pazopanib and SBRT in metastatic renal cell carcinoma.

Yasemin Benderli Cihan1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29740689     DOI: 10.1007/s00345-018-2323-6

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


× No keyword cloud information.
  6 in total

1.  Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.

Authors:  Jacob A Miller; Ehsan H Balagamwala; Lilyana Angelov; John H Suh; Brian Rini; Jorge A Garcia; Manmeet Ahluwalia; Samuel T Chao
Journal:  J Neurosurg Spine       Date:  2016-07-08

Review 2.  Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy.

Authors:  Erqi L Pollom; Lei Deng; Reetesh K Pai; J Martin Brown; Amato Giaccia; Billy W Loo; David B Shultz; Quynh Thu Le; Albert C Koong; Daniel T Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-07-01       Impact factor: 7.038

3.  Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT).

Authors:  Brandon M Barney; Svetomir N Markovic; Nadia N Laack; Robert C Miller; Jann N Sarkaria; O Kenneth Macdonald; Heather J Bauer; Kenneth R Olivier
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-09-01       Impact factor: 7.038

4.  Phase I trial of pazopanib in patients with advanced cancer.

Authors:  Herbert I Hurwitz; Afshin Dowlati; Shermini Saini; Shawna Savage; A Benjamin Suttle; Diana M Gibson; Jeffrey P Hodge; Elmar M Merkle; Lini Pandite
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

Review 5.  Systemic therapy in metastatic renal cell carcinoma.

Authors:  Jens Bedke; Thomas Gauler; Viktor Grünwald; Axel Hegele; Edwin Herrmann; Stefan Hinz; Jan Janssen; Stephan Schmitz; Martin Schostak; Hans Tesch; Stefan Zastrow; Kurt Miller
Journal:  World J Urol       Date:  2016-06-09       Impact factor: 4.226

6.  Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial.

Authors:  Katrien De Wolf; Sylvie Rottey; Karim Vermaelen; Karel Decaestecker; Nora Sundahl; Lizzy De Lobel; Els Goetghebeur; Gert De Meerleer; Nicolaas Lumen; Valérie Fonteyne; Daan De Maeseneer; Piet Ost
Journal:  Radiat Oncol       Date:  2017-09-22       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.